Image
Evidence-Based Best Practices

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Meeting Slides

Guidelines

Standards of medical care in diabetes—2015.

American Diabetes Association. Diabetes Care. 2015;38(suppl1):S1-S94.

AACE/ACE comprehensive diabetes management algorithm 2015.

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Endocr Pract.2015;21(4):438-447.

AACE/ACE clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015.

Handelsman Y, Bloomgarden ZT, Grunberger G, et al. Endocr Pract. 2015;21(suppl 1):1-87

Suggested Readings

Is insulin the most effective injectable antihyperglycaemic therapy?

Buse JB, Peters A, Russell-Jones D, et al. Diabetes Obes Metab. 2015;17(2):145-151.

Pharmacology, physiology, and mechanisms of incretin hormone action.

Campbell JE, Drucker DJ. Cell Metab. 2013;17:819-837.

Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk.

Chow E, Bernjak A, Williams S, et al. Diabetes. 2014;63(5):1738-1747.

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Diamant M, Nauck MA, Shaginian R, et al. Diabetes Care. 2014;37(10):2763-2773.

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.

Eng C, Kramer CK, Zinman B, Retnakaran R. Lancet. 2014;384(9961):2228-2234.

Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus.

Harris KB, McCarty DJ. Ther Adv Endocrinol Metab. 2015;6(1):3-18.

Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.

Sun F, Chai S, Li L, et al. J Diabetes Res. 2015;2015:157201.

Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.

Wang T, Wang F, Gou Z, et al. Diabetes Obes Metab. 2015;17(1):32-41.

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.

Wysham CH, MacConell LA, Maggs DG, et al. Mayo Clin Proc. 2015;90(3):356-365.

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists